| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 19.99 | 23.7% | 18.5% |
| Total Income | 19.99 | 23.7% | 18.5% |
| Expenditure | 26.45 | 8.5% | 4.5% |
| PBT | -2.89 | 104.0% | 71.2% |
| Net Profit | 3.62 | 93.4% | 128.5% |
| OPM | -32.29% | 21.89pp | 31.96pp |
| NPM | 18.08% | 81.91pp | 93.36pp |
| EPS | 0.07 | 93.6% | 126.9% |
Theravance Biopharma Reports Q3 2025; YUPELRI Net Sales Reach $71.4M
04 May 2026 · 4 May, 7:30 am
Summary
Theravance Biopharma reported strong Q3 2025 results, highlighted by record YUPELRI net sales of $71.4 million, a 15% increase year-over-year. The company achieved non-GAAP breakeven, underscoring its commitment to financial and operational discipline. The open-label portion of the pivotal Phase 3 CYPRESS study of ampreloxetine is now complete, with topline results expected in Q1 2026. Total revenue for the quarter was $20.0 million, up 19% compared to the same period in 2024, and net income was $3.6 million, a significant improvement from the net loss of $12.7 million in Q3 2024.
Key Highlights
- 1
YUPELRI net sales reached an all-time high of $71.4 million in Q3 2025, up 15% year-over-year.
- 2
The open-label portion of the pivotal Phase 3 CYPRESS study of ampreloxetine is now complete, with topline readout on track for Q1 2026.
- 3
TRELEGY year-to-date sales are on track to achieve a $50 million milestone in 2025.
- 4
Theravance Biopharma reported total revenue of $20.0 million for the third quarter of 2025, a 19% increase compared to Q3 2024.
- 5
Net income for Q3 2025 was $3.6 million, compared to a net loss of $12.7 million in the same period in 2024.
- 6
The company's cash position remains strong with $333 million in cash and no debt as of September 30, 2025.
- 7
Non-GAAP net income from operations was $2.3 million in the third quarter of 2025, compared to a non-GAAP net loss of $2.9 million in the same period in 2024.
Management Comments
Rick E Winningham
“Theravance delivered strong results in the third quarter, highlighted by record YUPELRI net sales and the achievement of non-GAAP breakeven, underscoring our commitment to financial and operational discipline. In parallel, we continue to advance ampreloxetine toward topline results from the pivotal Phase 3 CYPRESS study in the first quarter of 2026. Backed by a strong balance sheet, durable YUPELRI cash flow, and multiple high-value milestones ahead, we approach this important catalyst from a position of strength—ready to deliver results that could transform the standard of care for multiple system atrophy patients and drive lasting value for patients and shareholders.”
Informational and educational content only. Not investment advice.